|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N04BX01
|
|
gptkbp:bioavailability
|
65%
|
|
gptkbp:CASNumber
|
134308-13-7
|
|
gptkbp:contraindication
|
gptkb:liver_disease
|
|
gptkbp:developedBy
|
gptkb:Roche
|
|
gptkbp:eliminationHalfLife
|
2-3 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C14H11NO5
|
|
gptkbp:IUPACName
|
3,4-dihydroxy-4'-methyl-5-nitrobenzophenone
|
|
gptkbp:KEGGID
|
D02341
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:catechol-O-methyltransferase_inhibitor
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
273.24 g/mol
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1427
60733
DB00323
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:Sleep_disorder
nausea
diarrhea
hepatotoxicity
dyskinesia
|
|
gptkbp:synonym
|
Ro 40-7592
Tasmar
|
|
gptkbp:UNII
|
QSH1HPI1PM
|
|
gptkbp:usedFor
|
gptkb:Parkinson's_disease
|
|
gptkbp:bfsParent
|
gptkb:catechol-O-methyl_transferase
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tolcapone
|